trans-β-(4-Methoxy-phenylmercapto)-acrylsaeure | 714-31-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: trans-β-(4-Methoxy-phenylmercapto)-acrylsaeure
• 英文别名: (E)-3-(4-methoxyphenyl)sulfanylprop-2-enoic acid
• CAS: 714-31-8
• 化学式: C₁₀H₁₀O₃S
• 分子量: 210.254
• InChiKey: UWMBTHXPFXCCHA-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  trans-β-(4-Methoxy-phenylmercapto)-acrylsaeure 在 溴 、 溶剂黄146 作用下， 生成 ethynyl(4-methoxyphenyl)sulfane
  参考文献：
  名称：

  Angeletti et al., Gazzetta Chimica Italiana, 1957, vol. 87, p. 1115,1122

  摘要：

  DOI：
• 作为产物：
  描述：

  4-甲氧基苯硫酚 、 反-3-氯丙烯酸 在 乙醇 、 碳酸氢钠 作用下， 生成 trans-β-(4-Methoxy-phenylmercapto)-acrylsaeure
  参考文献：
  名称：

  Montanari; Negrini, Ricerca Scientifica, 1957, vol. 27, p. 3055,3056, 3057

  摘要：

  DOI：

文献信息

• QUINUCLIDINE ACRYLAMIDES
  申请人：AstraZeneca AB

  公开号：EP1235826A1

  公开（公告）日：2002-09-04
• US6642246B1
  申请人：——

  公开号：US6642246B1

  公开（公告）日：2003-11-04
• [EN] QUINUCLIDINE ACRYLAMIDES<br/>[FR] ACRYLAMIDES DE QUINUCLIDINE
  申请人：ASTRAZENECA AB

  公开号：WO2001029034A1

  公开（公告）日：2001-04-26

  A compound of formula (I) wherein A represents (II), (III), (IV), (V) or (VI); R represents hydrogen or methyl; R?1 and R2¿ are independently hydrogen, or C¿1?-C4 alkyl; R?3 and R4¿ are independently hydrogen, C¿1?-C4 alkyl or SAr, provided that at least one of R?3 and R4¿ represents SAr; Ar represents a 5- or 6-membered aromatic or heteroaromatic ring containing zero to three nitrogen atoms, zero or one oxygen atom, and zero or one sulfur atom or an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atom, and zero to one sulfur atom which may optionally be substituted with one or more substituents selected from: hydrogen, halogen, C¿1?-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, aryl, heteroaryl, -CO2R?5¿, -CN, -NO¿2?, -NR?6R7, -CF¿3, -OR?8; R5, R6, R7, and R8¿ are independently hydrogen, C¿1?-C4 alkyl, aryl, heteroaryl, -C(O)R?9¿, -C(O)NHR10, -C(O)R11, -SO2R?12, or, R6 and R7¿ may together be (CH¿2?)jQ(CH2)k where Q is O, S, NR?13¿, or, a bond; j is 2 to 7; k is 0 to 2; R?9, R10, R11, R12, and R13¿, are independently C¿1?-C4 alkyl, aryl, or heteroaryl; or an enantiomer thereof, and the pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.